STOCK TITAN

Glaukos Corporation - GKOS STOCK NEWS

Welcome to our dedicated news page for Glaukos Corporation (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Glaukos Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Glaukos Corporation's position in the market.

Rhea-AI Summary
Glaukos (NYSE: GKOS) has released its 2023 Sustainability Report, showcasing its commitment to corporate sustainability initiatives. The report highlights actions taken in 2023, including donations to underserved regions, employee benefits programs, and ISO 14001 certification. Glaukos aims to enhance stakeholder value while focusing on sustainability for the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Glaukos (NYSE: GKOS) is set to announce its first quarter 2024 financial results on May 1, 2024. The company, known for its innovative therapies in ophthalmology, will host a conference call and webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Summary
Glaukos (NYSE: GKOS) receives a new J-code, J7355, effective July 1, 2024, for iDose TR, a prostaglandin analog for reducing intraocular pressure. The code aims to enhance patient access in the U.S. and streamline billing processes. CMS also assigns CPT codes 0660T and 0661T for iDose TR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.4%
Tags
none
Rhea-AI Summary
Glaukos (NYSE: GKOS) to present multiple scientific abstracts at the ASCRS annual meeting, showcasing advancements in glaucoma treatment and corneal health. Key presentations include efficacy of new treatments and outcomes of various procedures. The company aims to revolutionize interventional glaucoma care with innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences
-
Rhea-AI Summary
Glaukos Corporation (GKOS) reports record net sales of $82.4 million in Q4 2023, with a 16% increase year-over-year. The company also saw an 11% rise in net sales for the full year 2023, reaching $314.7 million. Glaucoma net sales increased by 15% in Q4 2023, while corneal health net sales rose by 19%. The company reaffirmed its 2024 net sales guidance of $350 million to $360 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) is set to release its fourth quarter and full year 2023 financial results on February 21, 2024. The company, focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, will host a conference call and webcast to discuss the results. The live webcast link will be available on the company's website, and a replay will be archived afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023. Total net sales for the fourth quarter and full year of 2023 are expected to be in excess of $81 million and $313 million, respectively. The company also reaffirms its 2024 net sales guidance range of $350 million to $360 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
none
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) received FDA approval for iDose TR, a revolutionary, micro-invasive, injectable treatment for glaucoma. The drug is designed to deliver long-duration, intracameral therapy for glaucoma patients. The FDA approval is based on robust Phase 3 clinical trials, and the company plans to commence commercial launch activities in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.36%
Tags
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) will participate in the Stifel Healthcare Conference on November 14, 2023, at 10:55 a.m. ET in New York City. The event will be available via live and archived webcast on the Glaukos website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
none
Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Stock Data

4.86B
47.54M
3.86%
105.02%
7.06%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Clemente

About GKOS

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde